Silencing of the chemokine CXC receptor 4 (CXCR4) hampers cancer progression and increases cisplatin (DDP)-sensitivity in clear cell renal cell carcinoma (ccRCC)

References

• Zhai W, Sun Y, Guo C, et al. LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals. Cell Death Differ. 2017;24(9):1502–1517.
   PubMed Web of Science ®Google Scholar
• Gild P, Ehdaie B, Kluth LA. Effect of obesity on bladder cancer and renal cell carcinoma incidence and survival. Curr Opin Urol. 2017;27(5):409–414.
   PubMed Web of Science ®Google Scholar
• Saad AM, Gad MM, Al-Husseini MJ, et al. Trends in renal-cell carcinoma incidence and mortality in the United States in the last 2 decades: a SEER-based study. Clin Genitourin Cancer. 2019;17(1):46–57.e5.
   PubMed Web of Science ®Google Scholar
• Atkins MB, Tannir NM. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat Rev. 2018;70:127–137.
   PubMed Web of Science ®Google Scholar
• Barata PC, Rini BI. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017;67(6):507–524.
   PubMed Web of Science ®Google Scholar
• Bergerot P, Lamb P, Wang E, et al. Cabozantinib in combination with immunotherapy for advanced renal cell carcinoma and urothelial carcinoma: rationale and clinical evidence. Mol Cancer Ther. 2019;18(12):2185–2193.
   PubMed Web of Science ®Google Scholar
• Ghali F, Patel SH, Derweesh IH. Current status of immunotherapy for localized and locally advanced renal cell carcinoma. J Oncol. 2019;2019:7309205.
   PubMed Web of Science ®Google Scholar
• Xue D, Wang H, Chen Y, et al. Circ-AKT3 inhibits clear cell renal cell carcinoma metastasis via altering miR-296-3p/E-cadherin signals. Mol Cancer. 2019;18(1):151.
   PubMed Web of Science ®Google Scholar
• Nogueira I, Dias F, Teixeira AL, et al. miRNAs as potential regulators of mTOR pathway in renal cell carcinoma. Pharmacogenomics. 2018;19(3):249–261.
   PubMed Web of Science ®Google Scholar
• Ran L, Liang J, Deng X, et al. miRNAs in prediction of prognosis in clear cell renal cell carcinoma. Biomed Res Int. 2017;2017:4832931.
   PubMed Web of Science ®Google Scholar
• Zhu J, Armstrong AJ, Friedlander TW, et al. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. J Immunother Cancer. 2018;6(1):4.
   PubMedGoogle Scholar
• Adashek JJ, Salgia MM, Posadas EM, et al. Role of biomarkers in prediction of response to therapeutics in metastatic renal-cell carcinoma. Clin Genitourin Cancer. 2019;17(3):e454–e460. DOI:10.1016/j.clgc.2019.01.004.
   PubMed Web of Science ®Google Scholar
• Saahene RO, Wang J, Wang ML, et al. The role of CXC chemokine ligand 4/CXC chemokine receptor 3-B in breast cancer progression. Biotech Histochem. 2019;94(1):53–59.
   PubMed Web of Science ®Google Scholar
• Pan H, Peng Z, Lin J, et al. Forkhead box C1 boosts triple-negative breast cancer metastasis through activating the transcription of chemokine receptor-4. Cancer Sci. 2018;109(12):3794–3804.
   PubMed Web of Science ®Google Scholar
• Mitchell A, Hasanali SL, Morera DS, et al. A chemokine/chemokine receptor signature potentially predicts clinical outcome in colorectal cancer patients. Cancer Biomark. 2019;26(3):291–301.
   PubMed Web of Science ®Google Scholar
• Xiao J, Lai H, Wei SH, et al. lncRNA HOTAIR promotes gastric cancer proliferation and metastasis via targeting miR-126 to active CXCR4 and RhoA signaling pathway. Cancer Med. 2019;8(15):6768–6779.
   PubMed Web of Science ®Google Scholar
• Bluemel C, Hahner S, Heinze B, et al. Investigating the chemokine receptor 4 as potential theranostic target in adrenocortical cancer patients. Clin Nucl Med. 2017;42(1):e29–e34.
   PubMed Web of Science ®Google Scholar
• Susek KH, Karvouni M, Alici E, et al. The role of CXC chemokine receptors 1-4 on immune cells in the tumor microenvironment. Front Immunol. 2018;9:2159.
   PubMed Web of Science ®Google Scholar
• Su S, Chen J, Yao H, et al. CD10(+)GPR77(+) cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness. Cell. 2018;172(4):841–856.e16.
   PubMed Web of Science ®Google Scholar
• Dayer R, Babashah S, Jamshidi S, et al. Upregulation of CXC chemokine receptor 4-CXC chemokine ligand 12 axis in invasive breast carcinoma: a potent biomarker predicting lymph node metastasis. J Cancer Res Ther. 2018;14(2):345–350.
   PubMed Web of Science ®Google Scholar
• Liu Q, Rexiati M, Yang Y, et al. Expression of chemokine receptor 4 was associated with poor survival in renal cell carcinoma. Med Oncol. 2014;31(4):882.
   PubMed Web of Science ®Google Scholar
• Wang L, Chen W, Gao L, et al. High expression of CXCR4, CXCR7 and SDF-1 predicts poor survival in renal cell carcinoma. World J Surg Oncol. 2012;10(1):212.
   PubMedGoogle Scholar
• Li G, Badin G, Zhao A, et al. Prognostic value of CXCR4 expression in patients with clear cell renal cell carcinoma. Histol Histopathol. 2013;28(9):1217–1222.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang L, Yang B, et al. Strong expression of chemokine receptor CXCR4 by renal cell carcinoma cells correlates with metastasis. Clin Exp Metastasis. 2009;26(8):1049–1054.
   PubMed Web of Science ®Google Scholar
• Berlato C, Khan MN, Schioppa T, et al. A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer. J Clin Invest. 2017;127(3):801–813.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang H, Wang H, et al. Long non-coding RNA DUXAP8 promotes the cell proliferation, migration, and invasion of papillary thyroid carcinoma via miR-223-3p mediated regulation of CXCR4. Bioengineered. 2021;12(1):496–506.
   PubMed Web of Science ®Google Scholar
• Trivedi R, Dihazi GH, Eltoweissy M, et al. The antioxidant protein PARK7 plays an important role in cell resistance to Cisplatin-induced apoptosis in case of clear cell renal cell carcinoma. Eur J Pharmacol. 2016;784:99–110.
   PubMed Web of Science ®Google Scholar
• Yan L, Ding B, Liu H, et al. Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma. Theranostics. 2019;9(26):8377–8391.
   PubMed Web of Science ®Google Scholar
• Liu W, Chen H, Wong N, et al. Pseudohypoxia induced by miR-126 deactivation promotes migration and therapeutic resistance in renal cell carcinoma. Cancer Lett. 2017;394:65–75.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Fang L, Zang Y, et al. CIP2A promotes proliferation, invasion and chemoresistance to cisplatin in renal cell carcinoma. J Cancer. 2018;9(21):4029–4038.
   PubMed Web of Science ®Google Scholar
• Balar AV, Castellano D, O’Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18(11):1483–1492.
   PubMed Web of Science ®Google Scholar
• Makimoto G, Ichihara E, Hotta K, et al. Randomized phase II study comparing mannitol with furosemide for the prevention of renal toxicity induced by cisplatin-based chemotherapy with short-term low-volume hydration in advanced non-small cell lung cancer: the OLCSG1406 study protocol. Acta Med Okayama. 2018;72(3):319–323.
   PubMed Web of Science ®Google Scholar
• Luo R, Firat E, Gaedicke S, et al. Cisplatin facilitates radiation-induced abscopal effects in conjunction with PD-1 checkpoint blockade through CXCR3/CXCL10-mediated T-cell recruitment. Clin Cancer Res. 2019;25(23):7243–7255.
   PubMed Web of Science ®Google Scholar
• Liu W, Wang W, Wang X, et al. Cisplatin-stimulated macrophages promote ovarian cancer migration via the CCL20-CCR6 axis. Cancer Lett. 2020;472:59–69.
   PubMed Web of Science ®Google Scholar
• Liu P, Li X, Lv W, et al. Inhibition of CXCL1-CXCR2 axis ameliorates cisplatin-induced acute kidney injury by mediating inflammatory response. Biomed Pharmacother. 2020;122:109693.
   PubMed Web of Science ®Google Scholar
• Zhuang XM, Zhou B. CXCR4 enhances cisplatin resistance of human tongue squamous cell carcinoma. J Oral Pathol Med. 2019;48(2):122–128.
   PubMed Web of Science ®Google Scholar
• Da C, Portella L, Ottaiano A, et al. High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer. Curr Cancer Drug Targets. 2012;12(6):693–702.
   PubMed Web of Science ®Google Scholar
• Yang Z, OuYang X, Zheng L, et al. Long intergenic noncoding RNA00265 promotes proliferation of gastric cancer via the microRNA-144-3p/Chromobox 4 axis. Bioengineered. 2021;12(1):1012–1025.
   PubMed Web of Science ®Google Scholar
• Jang YG, Go RE, Hwang KA, et al. Resveratrol inhibits DHT-induced progression of prostate cancer cell line through interfering with the AR and CXCR4 pathway. J Steroid Biochem Mol Biol. 2019;192:105406.
   PubMed Web of Science ®Google Scholar
• Yu X, Wang D, Wang X, et al. CXCL12/CXCR4 promotes inflammation-driven colorectal cancer progression through activation of RhoA signaling by sponging miR-133a-3p. J Exp Clin Cancer Res. 2019;38(1):32.
   PubMedGoogle Scholar
• Gravina GL, Mancini A, Colapietro A, et al. The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models. Tumour Biol. 2017;39(6):1010428317695528.
   Google Scholar
• Long X, Li L, Zhou Q, et al. Long non-coding RNA LSINCT5 promotes ovarian cancer cell proliferation, migration and invasion by disrupting the CXCL12/CXCR4 signalling axis. Oncol Lett. 2018;15(5):7200–7206.
   PubMed Web of Science ®Google Scholar
• Li WQ, Han J, Widlund HR, et al. CXCR4 pathway associated with family history of melanoma. Cancer Causes Control. 2014;25(1):125–132.
   PubMed Web of Science ®Google Scholar
• Cao Y, Hunter ZR, Liu X, et al. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells. Br J Haematol. 2015;168(5):701–707.
   PubMed Web of Science ®Google Scholar
• Yu TT, Wang CY, Tong R. ERBB2 gene expression silencing involved in ovarian cancer cell migration and invasion through mediating MAPK1/MAPK3 signaling pathway. Eur Rev Med Pharmacol Sci. 2020;24(10):5267–5280.
   PubMed Web of Science ®Google Scholar